Skip to main content
Triple threat: Novel agent shows potent T2D weight loss in phase 1
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Triple threat: Novel agent shows potent T2D weight loss in phase 1
User login
Username
Password
Reset your password
Concept
Lead
score
Type 2 Diabetes Mellitus
1
1
Weight Management
0
0.74
Weight Loss
0
0.99
GLP-1 Receptor Agonist
0
0.98
Receptors
0
0.53
Obesity
0
0.49
Patient Safety
0
0.43
Adverse Effects
0
0.29
Incretin Hormone
0
0.23
Cardiovascular Risk Management
0
0.18
Lipids Management
0
0.18
Drug and Treatment Safety
0
0.12
Heart
0
0.12
Hemoglobin A1c
0
0.08
Blood
0
0.06
Diarrhea
0
0.06
Europe
0
0.06
Hemoglobin
0
0.06
LDL Cholesterol
0
0.06
Nausea
0
0.06
Triglycerides
0
0.06
Specialty
Lead
score
Diabetes & Endocrinology
1
1
Cardiology
0
0.9
Edit Tags